glp 1 receptor agonist diabetes Trends in the Development of GLP-1 Agonists GLP-1R and Diabetes

doi:10.1016/j.lfs.2004.03.024 34

The key word in the safety data is "no increase in serious cardiovascular events." That said, the absence of evidence is not evidence of absence

Tirzepatide (Mounjaro, Zepbound) Strengths: Highest efficacy for both glucose control and weight loss Dual mechanism (GLP-1 + GIP) may provide unique benefits Once-weekly dosing Generally well-tolerated Considerations: Higher cost than semaglutide Less long-term safety data (newer medication) Cardiovascular outcome trial not yet complete (though expected to be positive) Best for: Patients prioritizing maximum weight loss

Helps Control Appetite GLP-1 blend assists with hunger management and steady energy

After two months, my goal is for patients to be down 20lbs...and after 3 months my hope is that 25lbs - 30lbs can be achieved

Common areas reported by those on weight loss programs include the upper arms, the back, the shoulders, and the thighs